Porton Capital has sold Acolyte Biomedica, a developer of technology to combat hospital acquired infections to 3M. Porton Capital first invested in Acolyte in 2004, participating in a £3.7m expansion round. In 2002, BioProjects International led a £2.6m investment in the pharmaceutial company. At the time of the exit, Porton Capital held close to 50% of the company.
Deal includes three manufacturing facilities located in Spain, which employ around 140 staff
GP acquired the care home group from Swiss Prime Site and will be the company's sole shareholder
Iris, Idinvest and historical backers invest in the manager of the eponymous social media app
GP uses its Mérieux Participations 3 fund, which held a first close on €200m in 2018